TY - JOUR
T1 - Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
T2 - A randomized placebo-controlled, double-blind trial
AU - Meyskens, Frank L.
AU - McLaren, Christine E.
AU - Pelot, Daniel
AU - Fujikawa-Brooks, Sharon
AU - Carpenter, Philip M.
AU - Hawk, Ernest
AU - Kelloff, Gary
AU - Lawson, Michael J.
AU - Kidao, Jayashri
AU - McCracken, John
AU - Albers, C. Gregory
AU - Ahnen, Dennis J.
AU - Turgeon, D. Kim
AU - Goldschmid, Steven
AU - Lance, Peter
AU - Hagedorn, Curt H.
AU - Gillen, Daniel L.
AU - Gerner, Eugene W.
PY - 2008/6
Y1 - 2008/6
N2 - Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas. Three hundred seventy-five patients with history of resected (≥3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline and clinical site. Follow-up colonoscopy was done 3 years after randomization or off-study. Colorectal adenoma recurrence was compared among the groups with log-binomial regression. Comparing the outcome in patients receiving placebos to those receiving active intervention, (a) the recurrence of one or more adenomas was 41.1% and 12.3% (risk ratio, 0.30; 95% confidence interval, 0.18-0.49; P<0.001); (b) 8.5% had one or more advanced adenomas, compared with 0.7% of patients (risk ratio, 0.085; 95% confidence interval, 0.011-0.65; P<0.001); and (c) 17 (13.2%) patients had multiple adenomas (>1) at the final colonoscopy, compared with 1 (0.7%; risk ratio, 0.055; 0.0074-0.41; P<0.001). Serious adverse events (grade ≥3) occurred in 8.2% of patients in the placebo group, compared with 11% in the active intervention group (P = 0.35). There was no significant difference in the proportion of patients reporting hearing changes from baseline. Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.
AB - Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas. Three hundred seventy-five patients with history of resected (≥3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline and clinical site. Follow-up colonoscopy was done 3 years after randomization or off-study. Colorectal adenoma recurrence was compared among the groups with log-binomial regression. Comparing the outcome in patients receiving placebos to those receiving active intervention, (a) the recurrence of one or more adenomas was 41.1% and 12.3% (risk ratio, 0.30; 95% confidence interval, 0.18-0.49; P<0.001); (b) 8.5% had one or more advanced adenomas, compared with 0.7% of patients (risk ratio, 0.085; 95% confidence interval, 0.011-0.65; P<0.001); and (c) 17 (13.2%) patients had multiple adenomas (>1) at the final colonoscopy, compared with 1 (0.7%; risk ratio, 0.055; 0.0074-0.41; P<0.001). Serious adverse events (grade ≥3) occurred in 8.2% of patients in the placebo group, compared with 11% in the active intervention group (P = 0.35). There was no significant difference in the proportion of patients reporting hearing changes from baseline. Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.
UR - http://www.scopus.com/inward/record.url?scp=55549132996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55549132996&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-08-0042
DO - 10.1158/1940-6207.CAPR-08-0042
M3 - Article
C2 - 18841250
AN - SCOPUS:55549132996
SN - 1940-6207
VL - 1
SP - 32
EP - 38
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 1
ER -